Opko Health Inc (OPK)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 4:33 PM ET
Opko Health Inc (OPK) Statistics
Opko Health (OPK) has a market cap of $1.25B and an enterprise value of $1.33B. It kept -29.51% of revenue as net income over the last 12 months. Its share count is down 3.95% from a year earlier.
Total Valuation
Enterprise value is 6.86% above the market cap, as debt exceeds cash.
| Market Cap | $1.25B |
|---|---|
| Enterprise Value | $1.33B |
| Latest price (Nov 17, 2026) | $1.62 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.4x and 1.1x. Its year-end P/S ranged from 0.9x to 4.6x from 2016 to 2025.
| P/S Ratio | 2.4x |
|---|---|
| Forward P/S | 3.0x |
| P/B Ratio | 1.1x |
| P/TBV Ratio | 5.8x |
Price Statistics
The stock is up 26.56% over 52 weeks and trades 1.25% above its 50-day average.
| Beta (1Y) | 0.84 |
|---|---|
| 52-Week Change | +26.56% |
| 1-Month Change | +0.62% |
| 3-Month Change | +10.96% |
| 6-Month Change | +40.87% |
| 5-Year Change | -56.20% |
| 10-Year Change | -82.38% |
| Total Return (1Y) | +26.56% |
| Total Return (3Y CAGR) | +4.25% |
| Total Return (5Y CAGR) | -17.79% |
| Return vs SPY (1Y) | +15.00% |
| Max Drawdown (1Y) | -23.70% |
| Max Drawdown (3Y) | -46.90% |
| Sharpe Ratio (1Y) | 0.43 |
| Correlation with SPY (1Y) | 0.21 |
| 50-Day Average | $1.60 |
| 200-Day Average | $1.37 |
| 52-Week Range | $0.98 to $1.86 |
| RSI (14 Days) | 47.0 |
| Average Volume (20 Days) | 3.36M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.97x current liabilities, and total debt is 0.43x shareholder equity.
| Current Ratio | 4.97x |
|---|---|
| Quick Ratio | 4.65x |
| Debt / Equity | 0.43x |
| Interest Coverage | 0.60x |
Returns and Efficiency
Return on invested capital is -6.17% over the last 12 months, against a 5-year average of -7.02%.
| Return on Equity (ROE) | -13.26% |
|---|---|
| Return on Assets (ROA) | -7.87% |
| Return on Invested Capital (ROIC) | -6.17% |
| Return on Capital Employed (ROCE) | -7.27% |
| ROE (5Y Average) | -11.62% |
| ROA (5Y Average) | -7.98% |
| ROIC (5Y Average) | -7.02% |
| Asset Turnover | 0.26x |
| Inventory Turnover | 4.80x |
| Receivables Turnover | 6.19x |
| Cash Conversion Cycle | 69 days |
Scores
OPK has an Altman Z-Score of -0.38, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.38 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $501.64M over the last 12 months is down 8.26% from the 12 months before.
| Revenue | $501.64M |
|---|---|
| Revenue Growth (YoY) | -8.26% |
| Gross Profit | $231.86M |
| Operating Income | -$127.71M |
| Pretax Income | -$159.12M |
| Net Income | -$148.06M |
| EBITDA | -$34.72M |
| EBIT | -$124.97M |
| Reported EPS (TTM) | -$0.17 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 59.57% of the $1.88B in total assets.
| Cash and Equivalents | $390.22M |
|---|---|
| Total Debt | $475.83M |
| Net Debt | $85.61M |
| Net Debt Per Share | $0.11 |
| Working Capital | $643.92M |
| Shareholder Equity | $1.12B |
| Book Value Per Share | $1.50 |
| Tangible Book Value | $207.64M |
| Tangible Book Per Share | $0.28 |
| Total Assets | $1.88B |
| Total Liabilities | $764.08M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $10.29M of capital spending, operating cash flow left -$135.34M of free cash flow.
| Operating Cash Flow | -$125.05M |
|---|---|
| Capital Expenditures | $10.29M |
| Free Cash Flow | -$135.34M |
| FCF Per Share | -$0.18 |
| Depreciation and Amortization | $90.25M |
| Share Repurchases | $41.93M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -25.46%, against a 5-year average of -16.07%.
| Gross Margin | 46.22% |
|---|---|
| Operating Margin | -25.46% |
| Pretax Margin | -31.72% |
| Net Margin | -29.51% |
| EBITDA Margin | -6.92% |
| EBIT Margin | -24.91% |
| FCF Margin | -26.98% |
| Gross Margin (5Y Average) | 32.58% |
| Operating Margin (5Y Average) | -16.07% |
| Net Margin (5Y Average) | -20.18% |
Growth
Revenue fell 15.45% a year over 3 years.
| Revenue Growth (3Y CAGR) | -15.45% |
|---|---|
| Revenue Growth (5Y CAGR) | -15.82% |
| Book Value Per Share Growth (2Y CAGR) | -5.34% |
Dividends and Yields
OPK does not pay a dividend. Its free cash flow yield is -11.19%.
| FCF Yield | -11.19% |
|---|---|
| Buyback Yield | 3.47% |
| Shareholder Yield | 3.47% |
Peer Position
Against 12 similar companies, OPK has the 10th highest P/S.
P/S RatioPeer median 3.5x
ROICPeer median 0.17%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +11.08%
| P/S Ratio | 2.4x vs 3.5x median |
|---|---|
| ROIC | -6.17% vs 0.17% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -8.26% vs +11.08% median |
Analyst Forecast
Consensus estimates put revenue growth at -28.04% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -28.04% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About OPK
What is OPK's market cap?
Opko Health has a market cap of $1.25B. Its enterprise value, which adds debt and subtracts cash, is $1.33B.
How many shares of OPK are outstanding?
Opko Health has 746.48M shares outstanding. The count is down 3.95% from a year earlier.
Does OPK pay a dividend?
No. Opko Health does not pay a dividend.
How much debt does OPK have?
Opko Health has $475.83M of total debt and $390.22M of cash and equivalents, a net debt position of $85.61M.
OPK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts